Growing community of inventors

Ramona, CA, United States of America

David Erick Wright

Average Co-Inventor Count = 2.05

ph-index = 4

The patent ph-index is calculated by counting the number of publications for which an author has been cited by other authors at least that same number of times.

Forward Citations = 62

David Erick WrightTheresa Rosario-Jansen (7 patents)David Erick WrightD Elliott Parks (5 patents)David Erick WrightJohn S O'Brien (1 patent)David Erick WrightD Elliot Parks (1 patent)David Erick WrightMichael T White (1 patent)David Erick WrightDavid Erick Wright (14 patents)Theresa Rosario-JansenTheresa Rosario-Jansen (7 patents)D Elliott ParksD Elliott Parks (5 patents)John S O'BrienJohn S O'Brien (11 patents)D Elliot ParksD Elliot Parks (11 patents)Michael T WhiteMichael T White (1 patent)
..
Inventor’s number of patents
..
Strength of working relationships

Company Filing History:

1. Myelos Corporation (7 from 11 patents)

2. Horizon Therapeutics Usa, Inc. (4 from 8 patents)

3. Horizon Pharma Rheumatology LLC (2 from 9 patents)

4. Crealta Pharmaceuticals LLC (1 from 2 patents)


14 patents:

1. 12188927 - Methods and kits for predicting infusion reaction risk and antibody-mediated loss of response by monitoring serum uric acid during PEGylated uricase therapy

2. 11982670 - Methods and kits for predicting infusion reaction risk and antibody-mediated loss of response by monitoring serum uric acid during pegylated uricase therapy

3. 11639927 - Methods and kits for predicting infusion reaction risk and antibody-mediated loss of response by monitoring serum uric acid during PEGylated uricase therapy

4. 11598767 - Methods and kits for predicting infusion reaction risk and antibody-mediated loss of response by monitoring serum uric acid during pegylated uricase therapy

5. 10823727 - Methods and kits for predicting infusion reaction risk and antibody-mediated loss of response by monitoring serum uric acid during pegylated uricase therapy

6. 10139399 - Methods and kits for predicting infusion reaction risk and antibody-mediated loss of response by monitoring serum uric acid during PEGylated uricase therapy

7. 9377454 - Methods and kits for predicting infusion reaction risk and antibody-mediated loss of response by monitoring serum uric acid during pegylated uricase therapy

8. 8063016 - Retro-inverso peptides derived from interleukin-6

9. 7754690 - Method of using retro inverso peptides derived from leukemia inhibitory factor

10. 7754688 - Methods of using retro-inverso peptides derived from interleukin-6

11. 7135461 - Retro-inverso peptides derived from interleukin-6

12. 7115571 - Retro-inverso peptides derived from interleukin-3

13. 7109168 - Retro-inverso peptides derived from leukemia inhibitory factor

14. 6458357 - Retro-inverso neurotrophic and analgesic peptides

Please report any incorrect information to support@idiyas.com
idiyas.com
as of
1/1/2026
Loading…